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Developing an eﬀective vaccine against HIV infection remains an urgent goal. We used a DNA prime/fowlpox virus boost regimen
to immunize Chinese rhesus macaques. The animals were challenged intramuscularly with pathogenic molecularly cloned SHIV-
KB9. Immunogenicity and protective eﬃcacy of vaccines were investigated by measuring IFN-γ levels, monitoring HIV-speciﬁc
binding antibodies, examining viral load, and analyzing CD4/CD8 ratio. Results show that, upon challenge, the vaccine group can
induce a strong immune response in the body, represented by increased expression of IFN-γ, slow and steady elevated antibody
production, reduced peak value of acute viral load, and increase in the average CD4/CD8 ratio. The current research suggests that
rapid reaction speed, appropriate response strength, and long-lasting immune response time may be key protection factors for
AIDS vaccine. The present study contributes signiﬁcantly to AIDS vaccine and preclinical research.
1.Introduction
Human immunodeﬁciency virus type 1 (HIV-1) is the ae-
tiological agent of acquired immune deﬁciency syndrome
(AIDS). Since the ﬁrst case of HIV-1 infection was reported
in Los Angeles in 1981 [1], more than 68 million people
have been infected with HIV worldwide. Nearly 25 million
people have died, and approximately 33.3 million people are
suﬀering from HIV globally at the end of 2009 according to
the 2010 global report published by the Joint United Nations
Programme on HIV/AIDS [2]. AIDS/HIV remains the
deadliest crisis and the greatest social, economic, and public
health challenge in modern times because of the absence of
eﬀective prophylaxis or therapy methods [3–9].
Undoubtedly, the best and most economical solution to
eradicateorcontrolthespreadofHIV-1istodevelopsafeand
eﬀective vaccine. Although considerable eﬀorts have been
devoted toward this goal, the success of available vaccines
has not been demonstrated [3, 4, 10, 11]. Previous studies
have determined that the HIV-speciﬁc CD8+ cytotoxic T-
cell responses play key roles in controlling viral replication,
which could reduce viral loads and postpone disease pro-
gression in individuals who are infected with HIV-1 [12–16].
Immunization with polyvalent antigens may likely stimulate
more eﬀective immunity than a single antigen as described
in an earlier study [12, 17]. Thus, combining multi-CTL
epitopes derived from diﬀerent genes of HIV-1 to construct
a chimeric antigen may be a better strategy to develop new
vaccines. Previously, we designed and constructed a new
immunogen, which includes 29 multiepitopes and the p24
protein of HIV-1 as carrier molecule. The selected epitopes
coveredthemostdominantepitopesderivedfromstructural,
regulatory, and accessory proteins of HIV, such as Gag, Env,
Pol, RT, IN, Vpr, Tat, and Nef; HLA-DR epitope, ER signal
peptide, and Kozak sequence were considered as well. The2 Clinical and Developmental Immunology
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Figure 1: Schematic representation of the rDNA and rFPV vaccine constructs. The functional elements of the expression vector are the
following. PCMV: human cytomegalovirus (CMV) immediate-early promoter/enhancer; Kozak: a Kozak translation-initiation sequence and
an initiation codon (ATG) for proper initiation of translation; ER signal: endoplasmic reticulum signal peptide; MEG(4): multi-epitope gene
(including 4 epitopes); P24: HIV-1 capsid protein; MEG(25): multi-epitope gene (including 25 epitopes); BGHpA: Bovine growth hormone
(BGH) polyadenylation signal; TKL: the left recombinant fowlpox virus; PE/L: early and late promoter of fowlpox virus; T5NT: terminal
signal of fowlpox virus; TKR: the right recombinant fowlpox virus.
antigenicityandimmunogenicitywereevaluatedinvitroand
in vivo [18–20].
To further conﬁrm the immunogenicity and protective
eﬀect of this vaccine, we immunized Chinese rhesu maca-
ques with a DNA prime/fowlpox virus boost regimen. These
animals were challenged intravenously with pathogenic
molecularly cloned SHIV-KB9. The monkeys were moni-
tored by measuring their IFN-γ levels, HIV-speciﬁc binding
antibodies, viral load, and CD4/CD8 ratio and by analyzing
the immunogenicity and the protective eﬀect of vaccine to
facilitate clinical trials.
2.MaterialsandMethods
2.1. Animals. Chinese-origin rhesus macaques (Ch Rh), 3–
5 years of age, both female and male, and with no signs of
clinical diseases, were provided by the Laboratory Animal
Center, Academy of Military Medical Sciences. Sixteen Chi-
nese rhesus macaques from Guangxi, aged 3–5 years, weigh-
ing 3–5kg, and without simian immunodeﬁciency virus
(SIV), monkey T lymphocytes of I virus (STLV), monkey
ART D-type virus (SRV/D), or B virus infection, were bred
and provided by the experimental Animal Center of Military
Medical Sciences. The present research project was approved
by the relevant ethics review committee. Animal husbandry
and sample collection were in accordance with relevant
biosecurity requirements.
2.2. Vaccines. The vaccines used in the current study are
recombinantDNAvaccinerDNA/pVMp24andrecombinant
fowlpox virus rFPV/Mp24. Both are epitope-based vaccines
containing the same immunogens, which includes a Kozak
translation initiation sequence, ER signal peptide, 29 HIV
dominant epitopes (24 CTL or CD8 T-cell epitopes and 5 B-
cellepitopes),andHIV-1p24protein.Theimmunogenswere
provided by professor Ningyi Jin of the Institute of Military
Veterinary Medicine, Academy of Military Medical Sciences.
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Figure 2: Immunization and challenge schedule. rDNA: recombi-
nant DNA; rFPV: recombinant FPV.
The schematic representation of the rDNA and rFPV vaccine
constructs is shown in Figure 1.
2.3. Immunization and Challenge Experiments. The Chinese
rhesus macaques were randomly divided into 2 groups (4
macaques per group). Each group was primed intramuscu-
larly (i.m.) with rDNA/pVMp24 (500μg/per animal) vaccine
and empty vector pVAX1 control at weeks 0, 4, and 10 and
subsequently boosted with 109 plaque-forming unit (PFU)
rFPV/Mp24 vaccine and wild-type FPV at week 18. At week
28, the macaques were challenged intravenously with 20
MID50 of SHIV-KB9 provided by professor Yiming Shao of
the Chinese Center for Disease Control and Prevention.
Theimmunizationscheduleandroutesofadministration
are outlined in Figure 2.
2.4. Sample Collection and Processing. In the presence of
EDTA anticoagulant, hind-limb venous blood was collected
at7,13,21,28,and35dpostinfection.Thesamplesweresent
to the laboratory within 6h. Part of the unclotted blood was
processed for blood routine examination and ﬂow analysis.
The remaining samples were centrifuged at 1700rpm and
kept at room temperature for 10min. Plasma was analyzed
for virus RNA load and antibodies. PBMC was sepa-
rated from the blood cell for enzyme-linked immunospotClinical and Developmental Immunology 3
(ELISPOT) and other analyses. Plasma was stored at −20◦C,
and the PBMC was frozen in liquid nitrogen.
2.5. IFN-γ ELISPOT Detection. ELISPOT assays were con-
ducted to evaluate the gamma interferon-(IFN-γ-)secreting
cells. PBMCs were isolated by Ficoll gradient centrifugation
as previously described [21]. ELISPOT responses were
detected using the monkey IFN-γ ELISPOT kit (U-CyTech
Biosciences, Utrecht, the Netherlands) according to the in-
structions of the manufacturer. Each sample was stimulated
in triplicate by adding a single pool of p24 peptides (15-
mer HIV-1 consensus p24 peptides with an 11-amino-acid
overlap, synthesized by HD Biosciences Co., Ltd., Shanghai,
China) with a ﬁnal concentration of 4μg/mL for each
peptide. PMA (50ng/mL) and ionomycin (1μg/mL) were
used as positive controls, whereas RPMI 1640 medium was
used as negative control. The results were indicated as spot-
forming cells (SFC)/million PBMC. A positive response was
deﬁned as 4 times ELISPOT points higher than the negative
control points and greater than 50 SFC/106 cells at each time
point.
2.6. Detection of HIV-1-Speciﬁc Binding Antibodies in the
Serum. Sequence alignment indicates that HIV-1 p24 and
SHIV p24 proteins have strong homology. Thus, the anti-
bodies induced by the SHIV virus have a strong cross-
immune response to the HIV antigen. In the present study,
the HIV-1-speciﬁc antibody responses were measured by the
third-generation total HIV-binding antibody diagnostic kit
(Vironostika HIV Uni-Form II Plus O, BioM´ erieux Corpo-
rate, France). The experiment was conducted by employing
the enzyme-linked immunosorbent assay according to the
protocols of the manufacturer and the literature.
2.7. Measurement of Plasma Viral RNA Load. The plasma
viral RNA was extracted by QIAGEN Viral RNA minikit
(QIAGEN company) and analyzed by real-time PCR using
TaqMan EZ RT-PCR Core Reagents kit (ABI Company) and
ABI Prism 7700 apparatus. SHIV viral RNA in the samples
was quantiﬁed by the standard curve derived from RNA
standards.
2.8. CD3, CD4, and CD8 Lymphocyte Subset Analysis. We
used three nonhuman primate antibodies, FITC-CD3,
PerCP-CD4, and PE-CD8 (BD Pharmingen Inc.) in the
ﬂow analysis. Each ﬂow tube contained 5μLo fe a c h
antibody and 100μL of whole blood. Bland control and
CD3-, CD4-, and CD8-stained controls were set up. The
contents were mixed evenly by shaking and incubated under
darkness at room temperature for 20min. During shaking,
1mL 1x PBS dissolved in 500μL hemolysin was added
to lyse the red blood cells. The mixture was kept for
10min until the liquid became translucent. Subsequently,
the mixture was centrifuged at 1500rpm for 5min. The
supernatant was discarded and the cells were scattered
by vibration. Formaldehyde ﬁxative (300μL) was added
and the samples were analyzed by ﬂow cytometry (BD
FACSCalibur).
Table 1: Whole-virus HIV-speciﬁc binding antibody titers after the
challenge.
Groups Animals
Whole-virus HIV-1 speciﬁc antibody titers
7 days 14 days 21 days 28 days 35 days
Control
M 1 00001
M 2 00001
M 3 00011
M 4 00000
Vaccine
M 5 00113
M 6 00012
M 7 00112
M 8 00123
2.9. Statistical Analysis. Diﬀerences between the groups were
analyzed by Student’s t-test. The results were expressed as
mean ± SD. P value < 0.05 was considered signiﬁcant.
3. Results
3.1. ELISPOT Test of IFN-γ. ELISPOT method was used
to determine the IFN-γ-secreting T-cell immune responses
stimulated by HIV-1 p24 peptide library. Compared with
the control animals, the vaccine group produced strong
ELISPOT positive responses after immunization, as shown
in Figure 3. Two weeks after rFPV booster immunization
(20w), the ELISPOT response was signiﬁcantly enhanced,
with an average of 437SFC/106 cells. One empty vector also
showed weak positive responses, indicating that fowlpox
virus vector itself has certain nonspeciﬁc T-cell responses.
After the SHIV-KB9 virus attacks, all animals in the
immunized group showed diﬀerent degrees of ELISPOT-
positive responses (peak in the range of 115–890 SFC/106
cells). At day 7 postinfection (29w), a rapid increase in
ELISPOT response was detected, and at day 21 (31w), the
ELISPOT response remained at an appropriate response
level. These results suggest that the vaccine produced in the
present study has good cellular memory immune response.
3.2. Measurement of Serum-Speciﬁc Binding Antibodies. The
antibody analysis results after infection are shown in Table 1.
The control group (A) showed weak positive response at day
35(M1-M2).M3showedpositiveresponseatdays28and35,
but the antibody titers did not increase. However, antibody
titers of all animals in the vaccine group showed slow,
steady rise. The antibody production time was signiﬁcantly
earlier (M5, M7, and M8 at day 21) than the other group,
indicating that the vaccine induced signiﬁcant humoral
immune memory response.
3.3. Measurement of Plasma Viral RNA Load. The results of
plasma viral RNA load are shown in Figure 4. The peak value
of average viral load appeared at day 17 in all the vaccine
groups, which was later than that in the control group (13d).
The peak value of the average was signiﬁcantly lower than
that of the negative control group (P<0.05), indicating4 Clinical and Developmental Immunology
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Figure 3: Number of IFN-γ-secreting PBMC was detected by ELISPOT after stimulation with p24 peptide pools at various times after
immunization and challenge. (a) Histogram bars represent the average number of spots per million cells detected in duplicate cultures
for each animal, after subtraction of the average number of spots found in duplicate control cultures of PBMC without stimulation. (b)
Dynamics of the IFN-γ response was observed throughout the experiment for each group.
that the vaccine has certain inhibitory eﬀects on virus
replication.
3.4. T-Lymphocyte Subset Analysis. Flow analysis of the T-
lymphocyte subsets is shown in Figure 5. When the rhesus
macaques were infected by the virus, all the animals in
the control group exhibited continuous decline in terms of
CD4/CD8 ratio, with the inversion phenomenon occurring
at day 13. During the entire experimental time, no recovery
of CD4/CD8 was detected. However, the overall average
ratio of CD4/CD8 in the vaccine group declined at ﬁrst and
subsequently increased, and the average ratio of CD4/CD8
recovered to a relatively higher level at day 35.
4. Discussion and Conclusion
SIV/rhesus macaques are the most eﬀective models for
the investigation of the mechanisms for HIV pathogenesis
and prevention [22, 23]. However, the antigenic diﬀerences
among SIV, HIV-1, and HIV-2 cause signiﬁcant limitations
to this model [24–26]. In recent years, the use of chimeric
simian/human immunodeﬁciency virus (SHIV) instead of
SIV as an infection model has increased [27]. Previously,
most HIV vaccine trials in monkeys involved Indian rhesus
macaques [28, 29]. The SHIV-KB9/Indian rhesus model
is widely used in numerous research institutions and has
become a reference model for the evaluation of the immune
protective eﬀects of various vaccines [30, 31]. However,
due to the shortage of Indian rhesus animal resources,
the Chinese rhesus population (comprising approximately
30 million Chinese wild rhesus macaques) has become an
important alternative source [32]. Previous studies have
suggested that Chinese rhesus macaques (ChR) are better
modelsforAIDSvaccineresearch[33–35].Thecurrentstudy
made use of the SHIV/Chinese rhesus model to evaluate
vaccine immunogenicity and protective eﬃcacy.
Previous studies have shown that natural viral antigen
may contain components with negative eﬀects on protective
responses including several immune suppression and im-
mune pathological sequences. These components can inter-
fere with the immune response and block the cell signaling
pathway,leadingtolossofbalanceforTh1/Th2typeimmune
response in the body [4, 36–39]. Consequently, this can
result in immune response deviation or defect. Therefore,
screening, alteration, or modiﬁcation of the natural antigen
at the level of epitope to remove negative factors on immune
response while ensuring response speciﬁcity is extremely
important for vaccine designing. In addition, vaccines with
only single antigen gene have no signiﬁcant immune eﬀects.
Thus, the vaccine design needs to incorporate multiple and
diﬀerent immunogens as well as structural variety to obtain
broad virus-speciﬁc immune response [17, 40, 41]. Thus,
the current research presents a multi-epitope gene based
on the advantageous HIV epitope using macromolecular
particle protein p24 as carrier molecule. The multi-epitope
genecontainsHIV-speciﬁcT-cellepitope,HIV-speciﬁcB-cell
epitope, universal Th epitope, B-cell epitope, and one B-cell
epitope from tetanus toxin (TT). In addition to the function
of structural proteins such as Gag, Env, and Pol, the vaccine
also strengthens the important role of nonstructural proteins
(vpr, nef, tat, etc.) in immune response and viral replication
control. For chronic infections, such as HIV, the cellular
immune response, particularly CTL, is of considerable sig-
nificance to clear virus-infected cells [42–44]. Thus, we
emphasized the epitopes of nonstructural proteins of HIV,
and these epitopes were selected mainly from the classic,
advantageous kind with conservation capacity, broad cross-
reactivity, and have been proven in both patients and animal6 Clinical and Developmental Immunology
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Figure 4: Plasma viral load analysis post-SHIV-KB9 challenge. Viremia was quantiﬁed by RT-PCR. (a) Dynamics of viral load for each
group. (b) Average value of viral load for each group.
experiments. This will allow focusing on the nonstruc-
tural protein CTL of HIV. Considering the new features
of domestic and Asian HIV epidemic, the epitope was
adjusted based on the recently published HIV subtype at
GenBank (Genbank Accession Number AX149898). During
the vaccine construction, Kozak rules were considered.
Peptide signal sequence, codon preference, and other factors
that can increase antigen transcription and translation were
targeted, with the goal of achieving an eﬀective candi-
date vaccine with induction-speciﬁc immune response to
break the immune resistance to HIV antigens in the host.
Essentially, the aims are preventing and controlling HIV
infection as well as providing remedy to the disease after
vaccination.
“Prime-boost” immunization strategy is a sensational
topic in current vaccine study [45]. The ﬁrst reported use
of this strategy was in the immunization of inﬂuenza virus
[46]. Currently, this immunization strategy is widely used in
the research of a variety of pathogen vaccines, especially in
AIDS vaccine study [17, 41, 47].
In the study, we used an rDNA/rFPV “prime-boost”
coimmunization strategy to immunize the Chinese rhesus
macaques. Moreover, we used the SHIV-KB9 infection
to analyze the immune protective eﬀect of the vaccine.
The results show that, during the primary immuniza-
tion of rDNA/pVMp24 vaccine, the vaccine only induced
a relatively low level of IFN-γ-secreting T-cell immune
response in the immunized group, whereas after rFPV
booster immunization, the immune response signiﬁcantly
increased. This is consistent with the related literature
[41, 48]. The primary immunization of DNA vaccines can
induce high-aﬃnity T cells, but with low levels of immunity.
However, after fowlpox virus booster immunization, the
fowlpox enhances the immune eﬀect of primary immu-
nization through proinﬂammatory immune response of the
body.
IFN-γ-secreting T-cell immune response analysis per-
formed one week and three weeks after the SHIV-KB9
virus attack shows that when exposed to the virus, all the
vaccinated groups quickly activated antigen-speciﬁc CD8+Clinical and Developmental Immunology 7
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Figure 5: CD4/CD8 ratio analysis and total CD4 counts post-SHIV-KB9 challenge.
T-cell immunity. Rapid increase in ELISPOT response was
detected 7 days after infection and was maintained at an
appropriate response level at day 21. This indicates that the
vaccine eﬀectively extends the memory CD8+ T-cell survival
and maintains the capability of T-cell immune responses.
With regard to humoral immunity, we focused on the
production rate of p24 antibodies, antibody titers, and
antibody duration. The M1 and M2 in the negative control
group showed weak HIV-1 binding antibody response after
35 days of virus attack. M3 showed positive response at
days 28 and 35. However, the antibody titers did not
rise. M4 remained negative during the experiment. Three
animals in the immunized group (M5, M7, M8) showed
positive antibody response at day 21, and the antibody titers
exhibited a smooth, steady rise over time, indicating that
the immunized group eﬀectively induced the production of
speciﬁc antibodies.
Viral load is a major parameter which can be
used to evaluate whether HIV vaccine can induce immune
protection, and the viral load change after the viral attack
predicts the progress of the disease. In the present study,
the positive response of viral load appeared in the control
animals after 7 days of viral attack, and the peak value of
averageloadoccurredatday13.Incontrast,thepeakvalueof
the average load occurred at day 17 in the immunized group,
and the peak value was lower than that in the control group.
These results suggest that the vaccine delays the production
of virus peak point at the early-infection stage and reduces
the viral load at the peak point.
After virus infection, all the rhesus macaques in the
negative control group exhibited the inversion phenomenon
in CD4/CD8 ratio at day 13, and the ratio continued to
decline rapidly. No recovery of CD4/CD8 ratio was observed
during the experiment. However, in the immunized animals,8 Clinical and Developmental Immunology
the average CD4/CD8 ratio decreased at ﬁrst, subsequently
increased, and ﬁnally was restored to a relatively higher level
at day 35. This indicates that the vaccine eﬀectively induced
T-cell proliferation.
The fowlpox virus expression system in the study is a
newlydevelopedpoxvirusvectorbasedonvacciniavirusvec-
tor [48, 49]. The vector inherits the same advantages of
vaccinia virus vectors. Furthermore, the fowlpox virus has
a narrow host range and more safe [50, 51]. Except for
consideration on vectors, the immunogen design is also
a crucial factor for good vaccine. In the present study,
we selected and designed an optimal antigen combination
containing HIV-1 advantageous epitope by scanning and
analyzing the entire HIV-1 genome, searching the authorita-
tive database, and referring to the new features of Asian and
domestic HIV epidemic strains. In addition, we utilized p24
protein as a molecular scaﬀold. Based on the secure plasmid
DNA and the new FPV transfer vector, we constructed
the AIDS vaccine containing the above-mentioned antigens.
Thepreliminarymonkeyimmuneexperimentsandinfection
study show that this vaccine can decrease the peak value of
viral load at acute phase, delay the peak time, and make
the viral load rapidly decline. The results indicated that the
vaccine constructed in the current study has certain immune
protection eﬀects. And this provides new ideas and methods
for AIDS vaccine development. We are currently conducting
thesafety,qualitycontrol,andotherpreclinicalresearchesfor
this vaccine so as to move forward to the next phase of the
clinical study.
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